MiMedx Group Inc (MDXG)

Currency in USD
3.40
+0.06(+1.80%)
Closed·
3.400.00(-0.02%)
·
Earnings results expected today
MDXG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.323.41
52 wk Range
3.197.99
Key Statistics
Prev. Close
3.4
Open
3.35
Day's Range
3.32-3.41
52 wk Range
3.19-7.99
Volume
1.49M
Average Volume (3m)
1.18M
1-Year Change
-51.0981%
Book Value / Share
1.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDXG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.00
Upside
+135.29%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

MiMedx Group Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company’s wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company’s products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

MiMedx Group Inc SWOT Analysis


Market Dynamics
Explore MIMEDX's position in the $3.9 billion Advanced Wound Care and Surgical Markets, with projected growth in skin substitutes segment to $2.0 billion by 2026
Financial Resilience
Delve into MIMEDX's robust financial health, with 83.4% gross margin and 10.9% revenue growth, despite market challenges and regulatory headwinds
Clinical Excellence
Learn about MIMEDX's product differentiation, supported by over 50 publications showcasing strong clinical results, including a 97% wound closure rate for DFUs
Strategic Outlook
Discover MIMEDX's strategic initiatives, including new product launches and market expansion, with analyst targets around $11.00 per share
Read full SWOT analysis

MiMedx Group Inc Earnings Call Summary for Q4/2025

  • Q4 2025 revenue reached $118.1M, up 27% YoY; EPS of $0.14 beat forecast of $0.09 by 55.56%, driven by wound care and surgical product sales.
  • Full-year net sales hit $419M, marking 20% YoY growth; adjusted EBITDA reached $29M (25% of sales) with GAAP gross margin improving to 84%.
  • Stock declined 1.31% to $5.35 in aftermarket trading despite strong results, potentially reflecting Medicare reimbursement policy concerns.
  • Company projects Q2 2026 EPS of $0.03 and Q3 2026 EPS of $0.05; cautious outlook due to evolving Medicare reimbursement landscape challenges.
  • CEO Wright emphasized product portfolio strength and commitment to innovation amid regulatory changes; risks include reimbursement policy shifts.
Last Updated: 2026-02-25, 05:32 p/m
Read Full Transcript

Compare MDXG to Peers and Sector

Metrics to compare
MDXG
Peers
Sector
Relationship
P/E Ratio
10.4x18.4x−0.5x
PEG Ratio
0.78−0.050.00
Price/Book
2.0x2.1x2.6x
Price / LTM Sales
1.2x2.0x3.2x
Upside (Analyst Target)
124.6%166.1%48.8%
Fair Value Upside
Unlock27.3%7.6%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 8.00
(+135.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Buy7.00+105.88%10.00MaintainApr 20, 2026
Craig-Hallum
Buy7.00+105.88%10.00MaintainApr 17, 2026
Citizens
Buy10.00+194.12%-New CoverageFeb 23, 2026
Cantor Fitzgerald
Buy8.00+135.29%12.00MaintainFeb 17, 2026
Craig-Hallum
Buy10.00+194.12%13.00MaintainJan 23, 2026

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
0.14 / 0.09
Revenue / Forecast
118.1M / 106.94M
EPS Revisions
Last 90 days

MDXG Income Statement

People Also Watch

31.16
HRMY
+0.35%
8.07
GRFS
-0.74%
43.94
ACIW
+1.31%
94.73
TTC
-1.01%

FAQ

What Is the MiMedx (MDXG) Stock Price Today?

The MiMedx stock price today is 3.40 USD.

What Stock Exchange Does MiMedx Trade On?

MiMedx is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for MiMedx?

The stock symbol for MiMedx is "MDXG."

What Is the MiMedx Market Cap?

As of today, MiMedx market cap is 505.13M USD.

What Is MiMedx's Earnings Per Share (TTM)?

The MiMedx EPS (TTM) is 0.32.

When Is the Next MiMedx Earnings Date?

MiMedx will release its next earnings report on Apr 29, 2026.

From a Technical Analysis Perspective, Is MDXG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has MiMedx Stock Split?

MiMedx has split 0 times.

How Many Employees Does MiMedx Have?

MiMedx has 808 employees.

What is the current trading status of MiMedx (MDXG)?

As of Apr 29, 2026, MiMedx (MDXG) is trading at a price of 3.40 USD, with a previous close of 3.40 USD. The stock has fluctuated within a day range of 3.32 USD to 3.41 USD, while its 52-week range spans from 3.19 USD to 7.99 USD.

What Is MiMedx (MDXG) Price Target According to Analysts?

The average 12-month price target for MiMedx is 8.00 USD, with a high estimate of 10 USD and a low estimate of 6 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +135.29% Upside potential.

What Is the MDXG Premarket Price?

MDXG's last pre-market stock price is 3.45 USD. The pre-market share volume is 650.00, and the stock has decreased by 0.11, or 3.29%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.